Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Bristol-Myers Squibb Company (BMY) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 93,522,032
  • Shares Outstanding, K 1,671,230
  • Annual Sales, $ 16,560 M
  • Annual Income, $ 1,565 M
  • 36-Month Beta 0.94
  • Price/Sales 5.65
  • Price/Book 5.93

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.59 +8.18%
on 11/07/16
57.55 -3.02%
on 11/10/16
+4.80 (+9.41%)
since 11/04/16
3-Month
49.03 +13.83%
on 10/25/16
57.55 -3.02%
on 11/10/16
-1.15 (-2.02%)
since 09/06/16
52-Week
49.03 +13.83%
on 10/25/16
77.12 -27.63%
on 07/15/16
-13.30 (-19.24%)
since 12/04/15

Most Recent Stories

More News
Bristol-Myers Reports Data from Opdivo Combination Studies

Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.

Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer, From Phase 1/2 Study CheckMate -032

--Estimated two-year survival rate with the combination was 30% and was 17% with Opdivo monotherapy

CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody(TM) therapeutics for the treatment of cancer, today announced the selection of the fourth target...

Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda

This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.

Heat Biologics Stock Falls on Negative Bladder Cancer Data

Heat Biologics (HTBX) presented disappointing top-line phase II data from the bladder cancer study on its lead pipeline candidate, HS-410.

InvestorsObserver releases covered-call reports for Netflix, Cisco Systems, Apache Corporation, Bristol-Myers Squibb and Caterpillar Inc.

InvestorsObserver issues critical PriceWatch Alerts for APA, BMY, CAT, CSCO, and NFLX.

ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.

ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated...

Bristol-Myers Squibb to Take Part at the Citi 2016 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will take part in the Citi 2016 Global Healthcare Conference on Wednesday, December 7, 2016, in New York. Giovanni Caforio, M.D., chief executive...

The Zacks Analyst Blog Highlights: Bristol-Myers, Google, Deere, Halliburton and American Airlines

The Zacks Analyst Blog Highlights: Bristol-Myers, Google, Deere, Halliburton and American Airlines

AVEO Partner Submits Response to Questions on Tivozanib

AVEO Pharmaceuticals (AVEO) announced the submission of Day 120 List of Questions for tivozanib by EUSA Pharma.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain;...

See More

Support & Resistance

2nd Resistance Point 56.31
1st Resistance Point 55.93
Last Price 55.84
1st Support Level 55.20
2nd Support Level 54.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.